



ASX Announcement

25 June 2020

## Issue of Unlisted Securities

**Creso Pharma Limited (ASX:CPH, FRA:1X8) ('Creso Pharma' or 'the Company')** is pleased to advise that pursuant to the Appendix 3B released on 20 April 2020 at 3:55pm (AEST), the Company issued the following securities today:

- a) 1 CPHCON3 Convertible Note, with a face value of \$1,111,111; and
- b) 10,752,688 CPHOPT26 Options, which are exercisable at \$0.1386 each on or before 25 June 2023.

(together, the "**Securities**").

Following the issue of the above Securities, the Company's issued capital is as follows:

Type of Securities	Total Number of Securities
<b>Shares</b>	
CPH Ordinary Fully Paid Shares	347,371,189
<b>Options</b>	
CPHO Listed Options (\$0.80, 21/08/2020)	72,796,411
CPHOPT2 Options (\$0.40, 27/06/2020)	400,000
CPHOPT3 Options (\$0.20, 13/10/2020) <sup>1</sup>	2,886,250
CPHOPT5 Options (\$0.50, 23/01/2021)	300,000
CPHOPT12 Options (\$0.60, 27/07/2020)	100,000
CPHOPT14 Options (\$0.80, 13/07/2021) <sup>1</sup>	150,000
CPHOPT16 Options (\$0.535, 27/07/2021)	200,000
CPHOPT17 Options (\$0.80, 27/07/2022)	200,000
CPHOPT18 Options (\$0.55, 21/08/2021)	200,000
CPHOPT19 Options (\$0.80, 15/09/2022) <sup>1</sup>	400,000
CPHOPT20 Options (\$0.35, 12/02/2023)	2,128,387
CPHOPT21 Options (\$0.40, 12/02/2023)	6,847,725
CPHOPT22 Options (\$0.25, 1/03/2023)	250,000
CPHOPT23 Options (\$0.16, 10/03/2024) <sup>1</sup>	1,000,000
CPHOPT24 Options (\$0.20, 10/03/2024) <sup>1</sup>	1,000,000
CPHOPT25 Options (\$0.08, 10/03/2024) <sup>1</sup>	500,000
CPHOPT26 Options (\$0.1386, 25/06/2023)	10,752,688



CPHOPT28 Options (\$0.17, 2/06/2023)	36,764,706
CPHOPT29 Options (\$0.25, 2/06/2023)	4,000,000
CPHOPT31 Options (\$0.20, 2/06/2023)	8,000,000
<b><u>Performance Shares</u></b>	
CPHPERSB Performance Shares <sup>2</sup>	303,027
CPHPERSC Performance Shares <sup>2</sup>	303,027
CPHPERSD Performance Shares <sup>2</sup>	303,027
CPHPERSE Performance Shares <sup>2</sup>	303,039
<b><u>Performance Rights</u></b>	
CPHPERR6 Performance Rights (T1) <sup>1</sup>	800,000
CPHPERR7 Performance Rights (T2) <sup>1</sup>	800,000
CPHPERR16 Performance Rights (T17) <sup>1</sup>	100,000
<b><u>Employee Performance Rights (Under Plan)</u></b>	
CPHPERR22 Employee Performance Rights	33,000
CPHPERR23 Employee Performance Rights	33,000
CPHPERR24 Employee Performance Rights <sup>1</sup>	132,000
CPHPERR29 Employee Performance Rights <sup>1</sup>	300,000
CPHPERR32 Employee Performance Rights <sup>1</sup>	100,000
<b><u>Convertible Notes</u></b>	
CPHCON1 Tranche 1 Convertible Notes	3,264,192
CPHCON3 Convertible Note	1
CPHCON4 Convertible Notes	1,800,000

1. Subject to performance milestones and/or vesting conditions.
2. The performance milestone has not been satisfied and the Company intends to redeem these securities from holders in due course.

\*In addition to the above, there are also 8,300,000 exchangeable shares on issue in the Company's Nova Scotia subsidiary which may be exchanged for Shares in accordance with agreed ratios subject to conversion at the election of the holders.

For further information, refer to section 6.3 of the Cleansing Prospectus dated 23 June 2020, and released on ASX on 24 June 2020.

**Ends**

#### **Authority and Contact Details**

This announcement has been authorised for release by the Joint Company Secretaries of Creso Pharma Limited.



For further information, please contact:

**Investor Enquiries**

EverBlu Capital

E: [info@everblucapital.com](mailto:info@everblucapital.com)

P: +61 2 8249 0000

**Media Enquiries**

Ben Jarvis | Six Degrees Investor Relations

E: [ben.jarvis@sdir.com.au](mailto:ben.jarvis@sdir.com.au)

P: +61 413 150 448

**About Creso Pharma**

Creso Pharma Limited (ASX:CPH) brings the best of cannabis to better the lives of people and animals. It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. It develops cannabis and hemp derived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health. Creso Pharma uses GMP (Good Manufacturing Practice) development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids. To learn more please visit: [www.cresopharma.com](http://www.cresopharma.com)